Research Paper Volume 13, Issue 3 pp 4157—4181

CCDC167 as a potential therapeutic target and regulator of cell cycle-related networks in breast cancer

Drug testing for breast cancer cell lines and the survival of breast cancer patients. (A) Fluorouracil (5-Fu), carboplatin, paclitaxel, and doxorubicin treatments resulted in decreased cellular growths in MTT assays of MCF-7 cells. (B) Coiled-coil domain-containing protein 167 (CCDC167) mRNA alterations when treated with 5-Fu, carboplatin, paclitaxel, and doxorubicin for 2 days. (* pC) Correlation of CCDC167 recurrence-free survival and overall survival in Kaplan-Meier Plotter, using the GSE25307 dataset for recurrence-free survival and the GSE3494-GPL97 dataset for disease-specific survival in breast cancer patients. The red lines indicate high transcriptional expression levels of CCDC167, whereas the black lines indicate low expression levels. The plots also display hazard ratios (HRs), with 95% confidence intervals (CIs) and log-rank p values. High expression levels of CCDC167 predicted poor prognoses.

Figure 6. Drug testing for breast cancer cell lines and the survival of breast cancer patients. (A) Fluorouracil (5-Fu), carboplatin, paclitaxel, and doxorubicin treatments resulted in decreased cellular growths in MTT assays of MCF-7 cells. (B) Coiled-coil domain-containing protein 167 (CCDC167) mRNA alterations when treated with 5-Fu, carboplatin, paclitaxel, and doxorubicin for 2 days. (* p<0.05 was considered significant). (C) Correlation of CCDC167 recurrence-free survival and overall survival in Kaplan-Meier Plotter, using the GSE25307 dataset for recurrence-free survival and the GSE3494-GPL97 dataset for disease-specific survival in breast cancer patients. The red lines indicate high transcriptional expression levels of CCDC167, whereas the black lines indicate low expression levels. The plots also display hazard ratios (HRs), with 95% confidence intervals (CIs) and log-rank p values. High expression levels of CCDC167 predicted poor prognoses.